Ocular Inflammation
Conditions
Keywords
vitreoretinal surgery, epiretinal membrane, macular hole, non steroidal antinflammatory drugs, prostaglandin E2
Brief summary
The aim of this study is to determine vitreous levels of nonsteroidal antinflammatory drugs (NSAIDs) and prostaglandinE2 (PGE2) in eyes scheduled for vitrectomy. All patients received the study drugs for 3 days before surgery. 0.5 to 1.0 mL of undiluted vitreous was removed using the vitreous cutter positioned in the midvitreous cavity. Samples were immediately frozen and stored at -80°C until analysis. Sample analyses were performed using an high-performance liquid chromatography system. The lower limit of quantitation was 0.8 ng/mL. PGE2 levels were analyzed using the Prostaglandin E2 Monoclonal EIA Kit (Cayman Chemical Company) according to the manufacturer's instructions.
Interventions
OTHERPlacebo
Artificial tears for 3 days preoperatively
DRUGDicloftil
Dosing of drug 3 days prior to surgery
DRUGNevanac
Dosing of drug 3 days prior to surgery
DRUGIndom
Dosing of drug 3 days prior to surgery
DRUGYellox
Dosing of drug 3 days prior to surgery
Sponsors
University of Trieste
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* epiretinal membrane or full thickness macular hole scheduled for vitrectomy
Exclusion criteria
* vitreous hemorrhage * diabetes * glaucoma * concurrent retinovascular disease * previous ocular inflammation * previous ocular surgery * history of ocular trauma * previuos intravitreal injections * concomitant intake of topical or systemic NSAIDs or corticosteroid therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vitreous NSAIDs and PGE2 levels | 3 days after topical NSAID administration |
Countries
Italy
Outcome results
None listed